RNAZ Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

5.450

Open

5.285

VWAP

4.95

Vol

31.67K

Mkt Cap

5.08M

Low

4.700

Amount

156.76K

EV/EBITDA(TTM)

--

Total Shares

950.30K

EV

134.90M

EV/OCF(TTM)

--

P/S(TTM)

--

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Show More

Events Timeline

(ET)

2026-06-03

08:10:00

TransCode Therapeutics Advances TTX-MC138 to Phase 2a Clinical Trials

2026-05-27 (ET)

2026-05-27

08:10:00

TransCode Therapeutics Initiates Phase 2a Clinical Trial

2026-04-30 (ET)

2026-04-30

17:30:00

Transcode Therapeutics Files to Sell 15.96M Shares of Common Stock

2026-04-27 (ET)

2026-04-27

08:10:00

TransCode Executes Research Agreement with Michigan State University

2026-04-27

08:10:00

TransCode Therapeutics Appoints Anna Moore as Chair of Scientific Advisory Board

2026-04-07 (ET)

2026-04-07

08:40:00

TransCode Therapeutics Secures Up to $20M Financing Agreement

2026-03-03 (ET)

2026-03-03

08:10:00

TransCode Enters Exclusive License Agreement with Unleash

2026-02-05 (ET)

2026-02-05

08:10:00

TransCode Submits IND Amendment for TTX-MC138 Clinical Trial

2026-01-06 (ET)

2026-01-06

08:10:00

TransCode Therapeutics Publishes TTX-MC138 Research Findings

News

NASDAQ.COM

06-11NASDAQ.COM

Biotech Companies See Significant Stock Gains

PRnewswire

06-08PRnewswire

TransCode to Host Live Webcast on TTX-MC138 Phase 2a Trial and Pipeline

NASDAQ.COM

06-03NASDAQ.COM

Biotech Stocks Pre-Market Trading Insights

PRnewswire

06-03PRnewswire

TransCode Advances TTX-MC138 to Phase 2 Trials for ctDNA-Positive Cancers

PRnewswire

05-27PRnewswire

TransCode Initiates Phase 2a Clinical Trial for TTX-MC138

PRnewswire

04-27PRnewswire

TransCode Appoints New Chair of Scientific Advisory Board

Valuation Metrics

The current forward P/E ratio for Transcode Therapeutics Inc (RNAZ.O) is 0.00, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess Transcode Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.08

Current PE

0.00

Overvalued PE

0.53

Undervalued PE

-4.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

12.04

Current PS

0.00

Overvalued PS

36.35

Undervalued PS

-12.26

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stock averages a daily 5% gain

Intellectia · 195 candidates

Price Change Pct: >= $5.00

Ticker

Name

Market Cap$

Brand Engagement Network Inc

181.88M

Battalion Oil Corp

71.92M

Check Cap Ltd

25.74M

Smart Logistics Global Ltd

94.71M

Gauzy Ltd

26.05M

Solo Brands Inc

18.24M

Whales Holding RNAZ

Trading Trends

People Also Watch

Frequently Asked Questions

What is Transcode Therapeutics Inc (RNAZ) stock price today?

The current price of RNAZ is 4.7 USD — it has decreased -12.15

What is Transcode Therapeutics Inc (RNAZ)'s business?

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

What is the price predicton of RNAZ Stock?

Wall Street analysts forecast RNAZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAZ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Transcode Therapeutics Inc (RNAZ)'s revenue for the last quarter?

Transcode Therapeutics Inc revenue for the last quarter amounts to -7.19M USD, increased 154.63

What is Transcode Therapeutics Inc (RNAZ)'s earnings per share (EPS) for the last quarter?

Transcode Therapeutics Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Transcode Therapeutics Inc (RNAZ). have?

Transcode Therapeutics Inc (RNAZ) has 12 emplpoyees as of June 21 2026.

What is Transcode Therapeutics Inc (RNAZ) market cap?

Today RNAZ has the market capitalization of 5.08M USD.